Pfizer inflammatory disease drug hits goal in second study
Bio Pharma Dive
MARCH 29, 2022
The drugmaker said etrasimod, an experimental medicine acquired via its Arena buyout, improved remission rates in the second of two studies meant to support its approval in ulcerative colitis.
Let's personalize your content